SE445174B - Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans - Google Patents

Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans

Info

Publication number: SE445174B
Authority: SE; Sweden
Prior art keywords: cyclosporin; weight; parts; composition according; oil
Prior art date: 1978-03-07

Application number

SE7901683A

Other languages

English (en)

Swedish (sv)

Other versions

SE7901683L (sv

Inventor

T Cavanak

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-03-07

Filing date

1979-02-26

Publication date

1986-06-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25690510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE445174(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1978-03-07 Priority claimed from CH246178A external-priority patent/CH636013A5/de

1979-02-26 Application filed by Sandoz Ag filed Critical Sandoz Ag

1979-09-08 Publication of SE7901683L publication Critical patent/SE7901683L/xx

1986-06-09 Publication of SE445174B publication Critical patent/SE445174B/sv

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims description 24
108010036949 Cyclosporine Proteins 0.000 title claims description 24
229960001265 ciclosporin Drugs 0.000 title claims description 24
229930105110 Cyclosporin A Natural products 0.000 title claims description 22
229930182912 cyclosporin Natural products 0.000 title claims description 20
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
239000000126 substance Substances 0.000 title claims description 4
239000000203 mixture Substances 0.000 claims description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
239000003921 oil Substances 0.000 claims description 4
235000019198 oils Nutrition 0.000 claims description 4
239000002285 corn oil Substances 0.000 claims description 3
235000005687 corn oil Nutrition 0.000 claims description 3
108010040786 dihydrocyclosporin C Proteins 0.000 claims description 3
239000004006 olive oil Substances 0.000 claims description 3
235000008390 olive oil Nutrition 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
239000008158 vegetable oil Substances 0.000 claims description 2
238000005809 transesterification reaction Methods 0.000 claims 2
240000007817 Olea europaea Species 0.000 claims 1
229920001515 polyalkylene glycol Polymers 0.000 claims 1
150000002148 esters Chemical class 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000243 solution Substances 0.000 description 4
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
108010036941 Cyclosporins Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000035622 drinking Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241001149960 Tolypocladium inflatum Species 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

SE7901683A 1978-03-07 1979-02-26 Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans SE445174B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH246178A CH636013A5 (en)	1978-03-07	1978-03-07	More readily absorbable pharmaceutical composition
CH863478		1978-08-14

Publications (2)

Publication Number	Publication Date
SE7901683L SE7901683L (sv)	1979-09-08
SE445174B true SE445174B (sv)	1986-06-09

Family

ID=25690510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7901683A SE445174B (sv)	1978-03-07	1979-02-26	Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans

Country Status (27)

Country	Link
US (1)	US4388307A (no)
JP (1)	JPS54132223A (no)
AR (1)	AR223667A1 (no)
AT (1)	AT375828B (no)
AU (1)	AU528714B2 (no)
CA (1)	CA1139667A (no)
CY (1)	CY1285A (no)
DD (1)	DD142149A5 (no)
DE (1)	DE2907460A1 (no)
DK (1)	DK154539C (no)
ES (1)	ES478295A1 (no)
FI (1)	FI65914C (no)
FR (1)	FR2419072A1 (no)
GB (1)	GB2015339B (no)
HK (1)	HK48585A (no)
IE (1)	IE48016B1 (no)
IL (1)	IL56790A (no)
IT (1)	IT1115038B (no)
KE (1)	KE3516A (no)
MY (1)	MY8500134A (no)
NL (2)	NL187260C (no)
NO (2)	NO152635C (no)
NZ (1)	NZ189819A (no)
PH (1)	PH15159A (no)
PT (1)	PT69309A (no)
SE (1)	SE445174B (no)
SG (1)	SG14785G (no)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE54936B1 (en) *	1980-02-14	1990-03-28	Sandoz Ltd	A method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
DE3224619A1 (de) *	1981-07-14	1983-05-19	Freund Industrial Co., Ltd., Tokyo	Orale pharmazeutische zusammensetzung
US4525339A (en) *	1982-10-15	1985-06-25	Hoffmann-La Roche Inc.	Enteric coated oral dosage form
EP0127426A1 (en) *	1983-05-23	1984-12-05	Takeda Chemical Industries, Ltd.	Percutaneous pharmaceutical compositions for external use
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8903804D0 (en) *	1989-02-20	1989-04-05	Sandoz Ltd	Improvements in or relating to organic compounds
US5411951A (en) *	1984-10-04	1995-05-02	Monsanto Company	Prolonged release of biologically active somatotropin
US5474980A (en) *	1984-10-04	1995-12-12	Monsanto Company	Prolonged release of biologically active somatotropins
US4727035A (en) *	1984-11-14	1988-02-23	Mahoney Walter C	Immunoassay for cyclosporin
US4576645A (en) *	1984-12-06	1986-03-18	Block Drug Co., Inc.	Whipped gel composition
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤
US4775659A (en) *	1985-08-19	1988-10-04	Eli Lilly And Company	Injectable semi-solid formulations
GB8524421D0 (en) *	1985-10-03	1985-11-06	Boots Co Plc	Therapeutic agents
US4764381A (en) *	1985-12-06	1988-08-16	Key Pharmaceuticals, Inc.	Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
ATE80295T1 (de) *	1986-05-02	1992-09-15	Brigham & Womens Hospital	Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet.
US5118493A (en) *	1986-05-02	1992-06-02	Brigham And Women's Hospital	Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
KR880012221A (ko) *	1987-04-13	1988-11-26	사노 가즈오	에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
JP2577049B2 (ja) *	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
GB8717300D0 (en) *	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
US4839342A (en) *	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
AU620048B2 (en) *	1987-09-03	1992-02-13	University Of Georgia Research Foundation, Inc., The	Ocular cyclosporin composition
WO1989001772A1 (en) *	1987-09-03	1989-03-09	University Of Georgia Research Foundation, Inc.	Ocular cyclosporin composition
HU205010B (en) *	1987-09-15	1992-03-30	Sandoz Ag	Process for producing pharmaceutical compositions comprising compounds soluble up to 1 per cent and having medical activity
DE3830494B4 (de) *	1987-09-15	2006-05-18	Novartis Ag	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
US5756450A (en) *	1987-09-15	1998-05-26	Novartis Corporation	Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
EP0327280B1 (en) *	1988-01-29	1992-03-18	Sankyo Company Limited	Cyclosporin compositions
CH679119A5 (no) *	1988-05-13	1991-12-31	Sandoz Ag
HU201567B (en) *	1988-07-21	1990-11-28	Gyogyszerkutato Intezet	Process for production of intravenous medical compositions containing cyclosphorin
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) *	1988-09-16	1992-07-29	Sandoz Ltd	Pharmaceutical compositions containing cyclosporins
US5342625A (en) *	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
GR1000466B (el) *	1989-01-28	1992-07-30	Sandoz Ag	Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
GB2230440B (en) *	1989-02-09	1993-05-19	Sandoz Ltd	Novel cyclosporin galenic forms
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US4996193A (en) *	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
HU208491B (en) *	1990-11-27	1993-11-29	Gyogyszerkutato Intezet	Process for producing oral pharmaceutical composition containing cyclosporin
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
GB9113872D0 (en) *	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
ES2098739T3 (es)	1992-05-13	1997-05-01	Sandoz Ltd	Composiciones oftalmicas conteniendo una cyclosporin.
EP0570829B1 (de) *	1992-05-18	2001-04-25	CicloMulsion AG	Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US5637317A (en) *	1992-05-18	1997-06-10	Dietl; Hans	Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
CZ278863B6 (en) *	1992-09-07	1994-07-13	Galena	Medicinal preparations with n-methylated cyclic undecapeptides
EP0589843B1 (en)	1992-09-25	2001-11-28	Novartis AG	Pharmaceutical compositions containing cyclosporins
NZ247516A (en) *	1993-04-28	1995-02-24	Bernard Charles Sherman	Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
US20020099067A1 (en) *	1993-07-08	2002-07-25	Ulrich Posanski	Pharmaceutical compositions for sparingly soluble therapeutic agents
DE69435104D1 (de)	1993-09-28	2008-07-31	Scherer Gmbh R P	Herstellung von Weichgelatinekapseln
DE4340781C3 (de) *	1993-11-30	2000-01-27	Novartis Ag	Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
KR0146671B1 (ko) *	1994-02-25	1998-08-17	김충환	사이클로스포린-함유 분말 조성물
NZ270145A (en) *	1994-03-01	1996-08-27	Lilly Co Eli	Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
SE518578C2 (sv) *	1994-06-15	2002-10-29	Gs Dev Ab	Lipidbaserad komposition
AU2999995A (en) *	1994-07-22	1996-02-22	G.D. Searle & Co.	Self-emulsifying drug delivery system
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5603951A (en) *	1994-11-09	1997-02-18	Hanmi Pharm. Ind. Co., Ltd.	Cyclosporin-containing soft capsule compositions
HU215966B (hu) *	1994-11-21	1999-07-28	BIOGAL Gyógyszergyár Rt.	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
KR0167613B1 (ko) *	1994-12-28	1999-01-15	한스 루돌프 하우스, 니콜 케르커	사이클로스포린-함유 연질캅셀제 조성물
KR100239799B1 (ko) *	1995-01-21	2000-02-01	손경식	경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6696413B2 (en) *	1995-06-16	2004-02-24	Hexal Ag	Pharmaceutical preparation with cyclosporin A
SE504582C2 (sv) *	1995-07-06	1997-03-10	Gs Dev Ab	Cyklosporinkomposition baserad på en L2-fas
ATE263550T1 (de) *	1995-08-25	2004-04-15	Sangstat Medical Corp	Orale cyclosporinformulierungen
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
US5858401A (en) *	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US5958876A (en) *	1996-06-19	1999-09-28	Novartis Ag	Cyclosporin-containing pharmaceutical compositions
KR980008239A (ko) *	1996-07-26	1998-04-30	김충환	사이클로스포린-함유 약학적 조성물
US5798333A (en) *	1996-09-17	1998-08-25	Sherman; Bernard C.	Water-soluble concentrates containing cyclosporins
RU2211047C2 (ru)	1997-01-30	2003-08-27	Новартис Аг	Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
ATE286403T1 (de) *	1997-03-12	2005-01-15	Abbott Lab	Hydrophile binäre systeme zur verabreichung von cyclosporin
CA2285983A1 (en)	1997-04-29	1998-11-05	Bernard Charles Sherman	Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) *	1997-04-29	1998-07-28	Bernard Charles Sherman	Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
IN188719B (no) *	1997-09-08	2002-11-02	Panacea Biotec Ltd
US6187747B1 (en)	1997-09-08	2001-02-13	Panacea Biotech Limited	Pharmaceutical composition comprising cyclosporin
US6346511B1 (en)	1997-09-08	2002-02-12	Panacea Biotec Limited	Pharmaceutical composition comprising cyclosporin
US6008191A (en) *	1997-09-08	1999-12-28	Panacea Biotec Limited	Pharmaceutical compositions containing cyclosporin
US6063762A (en) *	1997-12-05	2000-05-16	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
KR19990047897A (ko) *	1997-12-05	1999-07-05	김충환	사이클로스포린 함유 약학적 조성물
US6028067A (en) *	1997-12-05	2000-02-22	Chong Kun Dang Corp.	Cyclosporin-containing microemulsion preconcentrate composition
PL348193A1 (en)	1998-12-11	2002-05-06	Pharmasolutions	Self-emulsifying compositions for drugs poorly soluble in water
IL143604A0 (en)	1998-12-30	2002-04-21	Dexcel Ltd	Dispersable concentrate for the delivery of cyclosporin
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
DE60023465T2 (de) *	1999-03-24	2006-07-20	R.P. Scherer Technologies, Inc., Las Vegas	Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6057289A (en) *	1999-04-30	2000-05-02	Pharmasolutions, Inc.	Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
EP1273287A1 (en) *	2000-04-04	2003-01-08	Shionogi & Co., Ltd.	Oily compositions containing highly fat-soluble drugs
WO2001097832A1 (de) *	2000-06-21	2001-12-27	Audit Institute For Medical Services And Quality Assurance Gmbh	Pharmazeutische zubereitungen enthaltend cyclosporine und neutralöle
AU2545901A (en)	2000-09-18	2002-03-26	Rpg Life Sciences Ltd	Selfemulsifiable formulation having enhanced bioabsorption and immunosuppressionactivities
CZ20033341A3 (cs) *	2001-06-21	2004-10-13	Pfizeráproductsáinc	Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
CA2452372A1 (en)	2001-07-06	2003-01-16	Sucampo Ag	Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
US7060672B2 (en) *	2001-10-19	2006-06-13	Isotechnika, Inc.	Cyclosporin analog formulations
WO2003043650A1 (en) *	2001-11-21	2003-05-30	Sucampo Ag	Use of fk506 and analogues for treating allergic diseases
EP1455753A1 (en) *	2001-12-20	2004-09-15	Bernard Charles Sherman	Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
KR20030065831A (ko) *	2002-02-01	2003-08-09	주식회사 태평양	사이클로스포린을 함유한 지속 방출형 약학적 조성물
US6828301B2 (en) *	2002-02-07	2004-12-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for hepatitis C viral protease inhibitors
GB2391471B (en) *	2002-08-02	2005-05-04	Satishchandra Punambhai Patel	Pharmaceutical compositions
GB2391472B (en) *	2002-08-02	2004-12-08	Satishchandra Punambhai Patel	Pharmaceutical compositions
GB2391473B (en) *	2002-08-02	2004-07-07	Satishchandra Punambhai Patel	Pharmaceutical compositions
KR100507771B1 (ko) *	2002-11-08	2005-08-17	한미약품 주식회사	난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US7842791B2 (en) *	2002-12-19	2010-11-30	Nancy Jean Britten	Dispersible pharmaceutical compositions
US6979672B2 (en)	2002-12-20	2005-12-27	Polichem, S.A.	Cyclosporin-based pharmaceutical compositions
US20040150061A1 (en) *	2003-01-30	2004-08-05	Hsin Chung Hsien	Package structure of a photosensor
ES2496102T3 (es) *	2003-03-28	2014-09-18	Sigmoid Pharma Limited	Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
TW200517114A (en)	2003-10-15	2005-06-01	Combinatorx Inc	Methods and reagents for the treatment of immunoinflammatory disorders
WO2005051293A2 (en)	2003-11-21	2005-06-09	Combinatorx, Incorporated	Methods and reagents for the treatment of inflammatory disorders
DE102004038980A1 (de) *	2004-08-10	2006-02-23	Cognis Deutschland Gmbh & Co. Kg	Antibeschlagmittel für Kunststoffe
WO2006035418A2 (en) *	2004-09-27	2006-04-06	Sigmoid Biotechnologies Limited	Microcapsules comprising a methylxanthine and a corticosteroid
US7135455B2 (en) *	2004-11-15	2006-11-14	Allergan, Inc	Methods for the therapeutic use of cyclosporine components
US7151085B2 (en) *	2004-11-15	2006-12-19	Allergan, Inc.	Therapeutic methods using cyclosporine components
US8673351B2 (en) *	2005-03-21	2014-03-18	Ivax Pharmaceuticals S.R.O.	Crystallization inhibitor and its use in gelatin capsules
US7288520B2 (en)	2005-07-13	2007-10-30	Allergan, Inc.	Cyclosporin compositions
US7202209B2 (en) *	2005-07-13	2007-04-10	Allergan, Inc.	Cyclosporin compositions
US20070015693A1 (en) *	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7276476B2 (en) *	2005-07-13	2007-10-02	Allergan, Inc.	Cyclosporin compositions
US20070015691A1 (en) *	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en) *	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US7501393B2 (en)	2005-07-27	2009-03-10	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en)	2005-10-14	2017-12-12	Allergan, Inc.	Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) *	2005-10-14	2010-06-29	Gregg Feinerman	Prevention and treatment of ocular side effects with a cyclosporin
KR20080065704A (ko)	2005-11-09	2008-07-14	콤비네이토릭스, 인코포레이티드	의학적 이상의 치료 방법들, 조성물들, 및 키트들
DK2079456T3 (da)	2007-04-04	2013-03-18	Sigmoid Pharma Ltd	Farmaceutiske cyclosporinsammensætninger
WO2008137617A1 (en) *	2007-05-04	2008-11-13	Allergan, Inc.	Use of cyclosporines in the treatment of patients with intraocular lenses
GB2451811A (en)	2007-08-09	2009-02-18	Ems Sa	Delivery composition for solubilising water-insoluble pharmaceutical active ingredients
TW200932240A (en) *	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
NZ593770A (en)	2009-01-08	2013-12-20	Allergan Inc	Compositions for enhancing nail growth
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US20110009339A1 (en) *	2009-04-14	2011-01-13	Allergan, Inc	Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
BRPI1012196B1 (pt)	2009-05-18	2021-11-30	Sublimity Therapeutics Limited	Composição compreendendo gotas de óleo
MY154683A (en)	2009-07-07	2015-07-15	Boehringer Ingelheim Int	Pharmaceutical composition for a hepatitis c viral protease inhibitor
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
CA3122934A1 (en)	2011-03-11	2012-09-20	Beth Israel Deaconess Medical Center, Inc.	Fusion protein comprising a fragment of cd40 and method of producing same
JP2014531468A (ja)	2011-10-05	2014-11-27	アラーガンインコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	爪の健康状態を増進するための組成物
KR20140096048A (ko)	2011-10-05	2014-08-04	알러간, 인코포레이티드	네일 건강을 강화시키는 조성물들
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
WO2016033556A1 (en)	2014-08-28	2016-03-03	Lipocine Inc.	BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
KR20170102223A (ko)	2014-11-07	2017-09-08	시그모이드 파마 리미티드	사이클로스포린을 포함하는 조성물
WO2017040932A1 (en)	2015-09-04	2017-03-09	Primatope Therapeutics Inc.	Humanized anti-cd40 antibodies and uses thereof
JPWO2017047299A1 (ja) *	2015-09-15	2017-12-21	富士フイルム株式会社	注射用液剤組成物
EP3544614A4 (en)	2016-11-28	2020-08-05	Lipocine Inc.	ORAL TESTOSTERONE UNDECANOATE THERAPY
AU2019308326A1 (en)	2018-07-20	2021-03-18	Lipocine Inc.	Liver disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1274354A (fr) *	1956-03-10	1961-10-27		Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
GB1110875A (en) *	1964-12-11	1968-04-24	Glaxo Lab Ltd	Compositions containing procaine penicillins
FR94740E (fr) *	1967-10-25	1969-10-24	Rhone Poulenc Sa	Nouveaux cyclopeptides et leur préparation.
NL167323C (nl) *	1970-09-26	1981-12-16	Organon Nv	Werkwijze ter bereiding van een psychofarmacologisch preparaat.
ES396746A1 (es) *	1971-11-06	1974-12-01	Gallardo Antonio Sa	Nuevo procedimiento de fabricacion de suspensiones establesidoneas para antibioticos.
CH574247A5 (en) *	1972-02-17	1976-04-15	Ciba Geigy Ag	Oily, injectable peptide/aluminium alkanoate compsns - - with prolonged duration of activity
JPS4891218A (no) *	1972-03-06	1973-11-28
AR207116A1 (es) *	1973-03-28	1976-09-15	Ciba Geigy Ag	Procedimiento para preparar nuevas dotriacontapeptidoamidas
DE2455859C2 (de) *	1973-12-06	1983-12-15	Sandoz-Patent-GmbH, 7850 Lörrach	Das Antibiotikum Cyclosporin A (S 7481/F-1), seine Herstellung und Verwendung
GB1547164A (en) *	1975-08-14	1979-06-06	Beecham Group Ltd	Veterinary compositions
CH614931A5 (no) *	1975-11-04	1979-12-28	Sandoz Ag
DE2555481C3 (de) *	1975-12-10	1985-10-03	Sandoz-Patent-GmbH, 7850 Lörrach	Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung

1979
- 1979-02-26 FI FI790640A patent/FI65914C/fi not_active IP Right Cessation
- 1979-02-26 SE SE7901683A patent/SE445174B/sv not_active IP Right Cessation
- 1979-02-26 DE DE19792907460 patent/DE2907460A1/de active Granted
- 1979-02-27 FR FR7904989A patent/FR2419072A1/fr active Granted
- 1979-02-27 NO NO790661A patent/NO152635C/no unknown
- 1979-02-27 IT IT48152/79A patent/IT1115038B/it active Protection Beyond IP Right Term
- 1979-02-28 DK DK086079A patent/DK154539C/da not_active IP Right Cessation
- 1979-03-02 CY CY1285A patent/CY1285A/xx unknown
- 1979-03-02 NL NLAANVRAGE7901703,A patent/NL187260C/xx active Protection Beyond IP Right Term
- 1979-03-02 GB GB7907395A patent/GB2015339B/en not_active Expired
- 1979-03-05 AT AT0163779A patent/AT375828B/de not_active IP Right Cessation
- 1979-03-05 NZ NZ189819A patent/NZ189819A/en unknown
- 1979-03-05 PT PT69309A patent/PT69309A/pt unknown
- 1979-03-05 ES ES478295A patent/ES478295A1/es not_active Expired
- 1979-03-05 IL IL56790A patent/IL56790A/xx unknown
- 1979-03-06 CA CA000322853A patent/CA1139667A/en not_active Expired
- 1979-03-06 DD DD79211409A patent/DD142149A5/de not_active IP Right Cessation
- 1979-03-06 PH PH22254A patent/PH15159A/en unknown
- 1979-03-06 AU AU44862/79A patent/AU528714B2/en not_active Expired
- 1979-03-07 JP JP2722879A patent/JPS54132223A/ja active Granted
- 1979-03-07 AR AR275732A patent/AR223667A1/es active
- 1979-08-08 IE IE704/79A patent/IE48016B1/en not_active IP Right Cessation
1982
- 1982-02-09 US US06/347,276 patent/US4388307A/en not_active Expired - Lifetime
1985
- 1985-02-27 SG SG147/85A patent/SG14785G/en unknown
- 1985-03-22 KE KE3516A patent/KE3516A/xx unknown
- 1985-06-20 HK HK485/85A patent/HK48585A/xx not_active IP Right Cessation
- 1985-12-30 MY MY134/85A patent/MY8500134A/xx unknown
1993
- 1993-07-02 NL NL930135C patent/NL930135I1/nl unknown
1994
- 1994-12-28 NO NO1994028C patent/NO1994028I1/no unknown

Also Published As

Publication number	Publication date
SE7901683L (sv)	1979-09-08
CA1139667A (en)	1983-01-18
DK154539C (da)	1989-05-16
FI65914C (fi)	1984-08-10
IT7948152A0 (it)	1979-02-27
AT375828B (de)	1984-09-10
PH15159A (en)	1982-08-24
DE2907460C2 (no)	1990-09-27
NO152635C (no)	1985-10-30
NO790661L (no)	1979-09-10
NO152635B (no)	1985-07-22
PT69309A (fr)	1979-04-01
HK48585A (en)	1985-06-28
AU4486279A (en)	1979-09-13
DK154539B (da)	1988-11-28
ES478295A1 (es)	1979-05-16
DD142149A5 (de)	1980-06-11
NL187260C (nl)	1991-08-01
IL56790A0 (en)	1979-05-31
IE48016B1 (en)	1984-09-05
US4388307A (en)	1983-06-14
AR223667A1 (es)	1981-09-15
NL930135I1 (nl)	1993-11-01
NL7901703A (nl)	1979-09-11
FR2419072B1 (no)	1983-04-22
FR2419072A1 (fr)	1979-10-05
IL56790A (en)	1982-01-31
DK86079A (da)	1979-09-08
FI65914B (fi)	1984-04-30
IE790704L (en)	1979-09-07
SG14785G (en)	1985-08-16
NO1994028I1 (no)	1994-12-28
AU528714B2 (en)	1983-05-12
JPS627891B2 (no)	1987-02-19
IT1115038B (it)	1986-02-03
ATA163779A (de)	1984-02-15
FI790640A (fi)	1979-09-08
KE3516A (en)	1985-04-19
GB2015339B (en)	1982-09-15
MY8500134A (en)	1985-12-31
GB2015339A (en)	1979-09-12
DE2907460A1 (de)	1979-09-13
JPS54132223A (en)	1979-10-15
CY1285A (en)	1985-07-05
NZ189819A (en)	1984-05-31

Publication	Publication Date	Title
SE445174B (sv)	1986-06-09	Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
CN1229136C (zh)	2005-11-30	供局部施用于眼组织的泪腺特异性乳状液
Rossini et al.	1978	Complete protection from low-dose streptozotocin-induced diabetes in mice
Bearn et al.	1955	Metabolic studies in Wilson's disease using Cu64
KR0170769B1 (ko)	1999-02-01	신규한 사이클로스포린 갈렌 제제
Murgia et al.	1996	The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients
Borel et al.	1995	The history of the discovery and development of cyclosporine (Sandimmune®)
KR100257841B1 (ko)	2000-09-01	사이클로스포린-함유약학적조성물
Vine et al.	1987	Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring
WO1997034622A1 (en)	1997-09-25	Oral cyclosporin formulations
EP3055325B1 (en)	2018-01-03	Novel derivative of an insulin analogue
UA34454C2 (uk)	2001-03-15	Фармацевтична композиція, що містить як активний компонент похідне циклоспорину
US5580574A (en)	1996-12-03	Pharmaceutical composition for transdermal delivery
Aoyama et al.	1997	Pharmacokinetics of recombinant human interleukin‐11 (rhIL‐11) in healthy male subjects
JP3862273B2 (ja)	2006-12-27	経口投与用シクロスポリン含有新規製剤
Chung et al.	1984	Human embryonic zeta-globin chains in adult patients with alpha-thalassemias.
TAKADA et al.	1985	Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles
WO1995029678A1 (en)	1995-11-09	Pharmaceutical composition for transdermal delivery
HU182920B (en)	1984-03-28	Process for preparing stable pharmaceutical compositions containing cyclosporin
Bowers et al.	1970	Activity-structure relationships of the thyrotropin releasing hormone
CA1187869A (en)	1985-05-28	Deca- undeca- dodeca and tridecapeptides with thymic activity
Ferland et al.	1976	Inhibition by six somatostatin analogs of plasma growth hormone levels stimulated by thiamylal and morphine in the rat
JPH0621072B2 (ja)	1994-03-23	エストラジオ−ル誘導体よりなる免疫調節剤
Saku et al.	1994	Plasma HDL levels are regulated by the catabolic rate of large particles of lipoprotein containing apo-AI
Lettieri et al.	1983	Effects of competitive red blood cell binding and reduced hematocrit on the blood and plasma levels of [14C] Indapamide in the rat.

Legal Events

Date	Code	Title	Description
1995-01-31	NAL	Patent in force	Ref document number: 7901683-8 Format of ref document f/p: F
1999-05-03	NUG	Patent has lapsed	Ref document number: 7901683-8 Format of ref document f/p: F

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 7901683-8

Format of ref document f/p: F

1999-05-03

NUG

Patent has lapsed